{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:33:47Z","timestamp":1770327227094,"version":"3.49.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Diffuse adult-type gliomas are delineated based on their molecular composition including the presence or absence of mutations in isocitrate dehydrogenase 1 or 2 (IDH1\/2), a key enzyme in the citric acid cycle. IDH-mutant tumors are associated with better survival than IDH-wildtype counterparts and can be further subdivided into astrocytoma or oligodendroglioma. Rare gliomas with fumarate hydratase (FH) deficiency have been reported. Given that FH is also a critical enzyme in the citric acid cycle, such tumors seem to be epigenetically similar to IDH-mutant tumors and, despite meeting criteria as IDH-wildtype gliomas per the current recommendations set forth by the World Health Organization, may behave in a manner akin to IDH-mutant neoplasms. Hereditary leiomyoma and renal cell cancer syndrome is associated with cutaneous and uterine leiomyomas and renal cell carcinoma caused by a germline FH alteration. To date, only rare examples of patients with known germline FH mutation subsequently diagnosed with a glioma have been reported. We report a case of a young patient with a glioma harboring features of IDH-mutant astrocytoma without evidence of IDH1\/2 alterations. After the identification of cutaneous FH-deficient leiomyomas, a retrospective analysis of his brain tumor revealed FH deficiency and a germline FH alteration was ultimately identified after further molecular studies. Although rare, we conclude that FH mutations seem to be part of the spectrum of alterations in diffuse gliomas.<\/jats:p>","DOI":"10.1097\/pas.0000000000002463","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T04:00:08Z","timestamp":1754971208000},"page":"132-137","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["A Case of a Fumarate Hydratase Deficient Astrocytoma in Association With a Germline Fumarate Hydratase Mutation With Review of the Literature"],"prefix":"10.1097","volume":"50","author":[{"given":"Rasha","family":"Alfattal","sequence":"first","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyadharsini","family":"Nagarajan","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Neuro-Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Quezado","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Aldape","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leomar Y.","family":"Ballester","sequence":"additional","affiliation":[{"name":"Pathology"},{"name":"Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-7958","authenticated-orcid":false,"given":"Maria A.","family":"Gubbiotti","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"R1-20251215","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"R2-20251215","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/jnci\/djq497","article-title":"DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma","volume":"103","author":"Christensen","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"R3-20251215","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"R4-20251215","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature16490","article-title":"Insulator dysfunction and oncogene activation in IDH mutant gliomas","volume":"529","author":"Flavahan","year":"2016","journal-title":"Nature"},{"key":"R5-20251215","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41588-017-0001-z","article-title":"Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence","volume":"50","author":"Turcan","year":"2018","journal-title":"Nat Genet"},{"key":"R6-20251215","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature10866","article-title":"IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype","volume":"483","author":"Turcan","year":"2012","journal-title":"Nature"},{"key":"R7-20251215","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/jnen\/nlac107","article-title":"Mutations of FH and IDH may induce gliomagenesis by similar mechanisms","volume":"82","author":"Raghunathan","year":"2022","journal-title":"J Neuropathol Exp Neurol"},{"key":"R8-20251215","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/jnen\/nlae100","article-title":"Long survival in a patient with fumarate hydratase mutation-associated glioma","volume":"84","author":"Reimann","year":"2025","journal-title":"J Neuropathol Exp Neurol"},{"key":"R9-20251215","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-020-2363-0","article-title":"Oncometabolites suppress DNA repair by disrupting local chromatin signalling","volume":"582","author":"Sulkowski","year":"2020","journal-title":"Nature"},{"key":"R10-20251215","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1111\/jdv.20139","article-title":"Hereditary cutaneous leiomyomatosis and low-grade glioma due to a fumarate hydratase mutation","volume":"39","author":"Laske","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R11-20251215","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"R12-20251215","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature19353","article-title":"Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition","volume":"537","author":"Sciacovelli","year":"2016","journal-title":"Nature"},{"key":"R13-20251215","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3892\/or.2024.8798","article-title":"Glioma lateralization: focus on the anatomical localization and the distribution of molecular alterations (Review)","volume":"52","author":"Cini","year":"2024","journal-title":"Oncol Rep"},{"key":"R14-20251215","doi-asserted-by":"crossref","first-page":"1536012119894087","DOI":"10.1177\/1536012119894087","article-title":"The relationship between IDH1 mutation status and metabolic imaging in nonenhancing supratentorial diffuse gliomas: A (11)C-MET PET Study","volume":"18","author":"Kudulaiti","year":"2019","journal-title":"Mol Imaging"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:03:33Z","timestamp":1765814613000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002463"}},"subtitle":["Considerations for Patients With Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome"],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002463","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"2025-05-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}